N-甲基-1-(噻吩并[3,2-c]吡啶-2-基)甲胺 | 709649-71-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩并吡啶类
• 中文名称: N-甲基-1-(噻吩并[3,2-c]吡啶-2-基)甲胺
• 中文别名: (3Z)-3-[2-(4-溴苯基)-2-羰基-亚乙基]-1-甲基-哌嗪-2-酮
• 英文名称: N-methyl-1-(thieno[3,2-c]pyridin-2-yl)methanamine
• 英文别名: methylthieno[3,2-c]pyridin-2-ylmethylamine；Methyl-thieno[3,2-c]pyridin-2-ylmethyl-amine；N-methyl-1-thieno[3,2-c]pyridin-2-ylmethanamine
• CAS: 709649-71-8
• 化学式: C₉H₁₀N₂S
• mdl: MFCD18453110
• 分子量: 178.258
• InChiKey: NRLQDHIBSGMYGV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  53.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-甲基-1-(噻吩并[3,2-c]吡啶-2-基)甲胺 、 (E)-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)acrylic acid dihydrochloride 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 DMF (N,N-dimethyl-formamide) 、 水 为溶剂， 以57%的产率得到(E)-N-methyl-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-N-thieno[3,2-c]pyridin-2-ylmethyl-acrylamide
  参考文献：
  名称：

  [EN] HETEROCYCLIC COMPOUNDS, METHODS OF MAKING THEM AND THEIR USE IN THERAPY
  [FR] COMPOSES HETEROCYCLIQUES, PROCEDES DE PRODUCTION DE CEUX-CI ET UTILISATION DE CEUX-CI DANS UN TRAITEMENT

  摘要：

  在某种程度上，本发明涉及公式（I）的抗菌化合物，其中A是一个双环杂芳基环或三环环，R2是一个杂环残基；L是一个键，或者L是烷基，烯基或环烷基。

  公开号：

  WO2004052890A1
• 作为产物：
  描述：

  噻吩并[3,2-c]吡啶 在 正丁基锂 作用下， 以 四氢呋喃 、 乙醇 、 正己烷 为溶剂， 反应 20.33h， 生成 N-甲基-1-(噻吩并[3,2-c]吡啶-2-基)甲胺
  参考文献：
  名称：

  Rational design of novel CYP2A6 inhibitors

  摘要：

  Inhibition of CYP2A6-mediated nicotine metabolism can reduce cigarette smoking. We sought potent and selective CYP2A6 inhibitors to be used as leads for drugs useful in smoking reduction therapy, by evaluating CYP2A6 inhibitory effect of novel formyl, alkyl amine or carbonitrile substituted aromatic core structures. The most potent CYP2A6 inhibitors were thienopyridine-2-carbaldehyde, benzothienophene-3-ylmethanamine, benzofuran-5-carbaldehyde and indole-5-carbaldehyde, with IC50 values below 0.5 mu M for coumarin 7-hydroxylation. Nicotine oxidation was effectively inhibited in vitro by two alkyl amine compounds and benzofuran-5-carbonitrile. Some of these molecules could serve as potential lead molecules when designing CYP2A6 inhibitory drugs for smoking reduction therapy. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2014.10.001

文献信息

• Compositions comprising multiple bioactive agents, and methods of using the same
  申请人：Berman M. Judd

  公开号：US20060142265A1

  公开（公告）日：2006-06-29

  In part, the present invention is directed to compositions comprising a FabI inhibitor and at least one other bioactive agent. In another part, the present invention is directed to antibacterial compositions comprising a compound of formulas I-III and at least one other antibacterial agent.

  本发明的一部分涉及含有FabI抑制剂和至少一种其他生物活性剂的组合物。另一部分，本发明涉及含有I-III式化合物和至少一种其他抗菌剂的抗菌组合物。
• Heterocyclic compounds, methods of making them and their use in therapy
  申请人：Berman Judd

  公开号：US20060183908A1

  公开（公告）日：2006-08-17

  In part, the present invention is directed to antibacterial compounds of formula (I) wherein A is a bicyclic heteroaryl ring or a tricyclic ring and R 2 is an heterocyclic residue; L is a bond, or L is alkyl, alkenyl or cycloalkyl.

  部分地，本发明涉及公式（I）中的抗菌化合物，其中A是双环杂芳基环或三环环，并且R2是杂环残基; L是键合或L是烷基，烯基或环烷基。
• Heterocyclic Compounds, Methods of Making Them and Their Use in Therapy
  申请人：Berman Judd

  公开号：US20110124633A1

  公开（公告）日：2011-05-26

  In part, the present invention is directed to antibacterial compounds.

  部分地，本发明涉及抗菌化合物。
• Compositions Comprising Multiple Bioactive Agents, and Methods of Using the Same
  申请人：BERMAN JUDD M.

  公开号：US20120010127A1

  公开（公告）日：2012-01-12

  In part, the present invention is directed to compositions comprising a FabI inhibitor and at least one other bioactive agent. In another part, the present invention is directed to antibacterial compositions comprising a compound of formulas I-III and at least one other antibacterial agent.

  本发明的一部分涉及包含FabI抑制剂和至少一种其他生物活性剂的组合物。另一部分涉及包含I-III式化合物和至少一种其他抗菌剂的抗菌组合物。
• HETEROCYCLIC COMPOUNDS, METHODS OF MAKING THEM AND THEIR USE IN THERAPY
  申请人：Debiopharm International SA

  公开号：EP1575951B1

  公开（公告）日：2014-06-25